Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial
Resource Expansion Drilling Confirms 3,000 metres of New Uranium Trends with Best Drill Hole of 1.4 GT over 7.6 metres
